echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Haizheng Pharmaceutical Co., Ltd. applied for clinical application of class 3.1 chemical drug API for sirolimus and was accepted

    Haizheng Pharmaceutical Co., Ltd. applied for clinical application of class 3.1 chemical drug API for sirolimus and was accepted

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, according to the website of the State Food and Drug Administration (CFDA), the 3.1 chemical raw material drug tirocimose and preparation injection tirocimose applied for clinical application by Haizheng pharmaceutical were accepted According to the data, tilsirolimus was developed by Wyeth company and approved by FDA and EU in 2007 for the treatment of metastatic renal cell carcinoma It is the first-line drug for advanced renal cell carcinoma Different from other drugs in the treatment of advanced renal cancer, ticolormis can inhibit the growth and proliferation of cells, decrease the level of vascular growth factor and prevent the development of new blood vessels In addition, the product is also effective for advanced metastatic breast cancer, mantle cell lymphoma, rheumatoid arthritis and multiple sclerosis According to CFDA, tiromos has not been listed in China The concentrated solution for injection of ticolormis, which was declared by Wyeth in 2008, has been approved by CFDA and has not yet been declared for production Apart from Haizheng pharmaceutical, no domestic enterprise has declared the product
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.